---
schema_version: "secwatch.filing_event.v1"
accession: "0001356576-26-000004"
form_type: "8-K"
ticker: "SUPN"
cik: "0001356576"
company_name: "SUPERNUS PHARMACEUTICALS, INC."
filed_at: "2026-02-24T23:59:59+00:00"
generated_at: "2026-05-16T00:44:55.843951+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Supernus Q4 revenue $211.6M (+21% YoY), FY revenue $719M (+9%); FY26 guidance $840-870M

## Summary
- Record Q4 total revenue $211.6M (+21% YoY); full year $719.0M (+9% YoY).
- Growth products (Qelbree, GOCOVRI, ZURZUVAE, ONAPGO) combined revenue $161.3M in Q4 (+45% YoY).
- ONAPGO net sales $8.9M since launch; new patient initiation resumed Q1 2026; second supplier expected 2027.
- Cash and marketable securities $308.7M at Dec 31, 2025.
- FY 2026 guidance: revenue $840-870M, operating earnings $0-30M, adjusted operating earnings $140-170M.

## SEC filing metadata
- accession: 0001356576-26-000004
- form_type: 8-K
- ticker: SUPN
- cik: 0001356576
- company_name: SUPERNUS PHARMACEUTICALS, INC.
- filed_at: 2026-02-24T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1356576/000135657626000004/0001356576-26-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1356576/000135657626000004/supn-20260224.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001356576-26-000004
- JSON: https://secwatch.observer/filing/0001356576-26-000004.json
- Plain text: https://secwatch.observer/filing/0001356576-26-000004.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.